Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
2.300
-0.010 (-0.43%)
Mar 6, 2026, 4:00 PM EST - Market closed
Allogene Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2017 |
| Revenue | - | 0.02 | 0.1 | 0.16 | 114.09 | - | Upgrade
|
| Revenue Growth (YoY) | - | -76.84% | -39.10% | -99.86% | - | - | Upgrade
|
| Cost of Revenue | 166.49 | 192.3 | 242.91 | 256.39 | 220.18 | 192.99 | Upgrade
|
| Gross Profit | -166.49 | -192.28 | -242.82 | -256.23 | -106.09 | -192.99 | Upgrade
|
| Selling, General & Admin | 58.53 | 65.21 | 71.67 | 79.31 | 74.11 | 65.26 | Upgrade
|
| Operating Expenses | 58.53 | 65.21 | 71.67 | 79.31 | 74.11 | 65.26 | Upgrade
|
| Operating Income | -225.02 | -257.48 | -314.49 | -335.54 | -180.19 | -258.24 | Upgrade
|
| Interest Expense | -0.84 | -0.18 | - | - | - | - | Upgrade
|
| Interest & Investment Income | 18.66 | 20.15 | 18.31 | 4.57 | 1.71 | 8.86 | Upgrade
|
| Earnings From Equity Investments | - | -1.69 | -10.67 | -12.88 | -4.09 | -67.31 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.03 | -0.28 | -0.16 | 3.44 | 0.52 | 0.31 | Upgrade
|
| EBT Excluding Unusual Items | -207.23 | -239.47 | -307.02 | -340.41 | -182.05 | -316.38 | Upgrade
|
| Gain (Loss) on Sale of Investments | -1.96 | -1.96 | -7 | - | - | - | Upgrade
|
| Asset Writedown | -2.38 | -15.72 | -13.25 | - | - | - | Upgrade
|
| Pretax Income | -211.57 | -257.15 | -327.27 | -340.41 | -182.05 | -316.38 | Upgrade
|
| Income Tax Expense | 0.44 | 0.44 | - | - | - | - | Upgrade
|
| Net Income | -212.02 | -257.59 | -327.27 | -340.41 | -182.05 | -316.38 | Upgrade
|
| Net Income to Common | -212.02 | -257.59 | -327.27 | -340.41 | -182.05 | -316.38 | Upgrade
|
| Shares Outstanding (Basic) | 217 | 195 | 157 | 143 | 136 | 120 | Upgrade
|
| Shares Outstanding (Diluted) | 217 | 195 | 157 | 143 | 136 | 120 | Upgrade
|
| Shares Change (YoY) | 17.65% | 24.14% | 9.63% | 5.39% | 12.84% | 19.11% | Upgrade
|
| EPS (Basic) | -0.98 | -1.32 | -2.09 | -2.38 | -1.34 | -2.63 | Upgrade
|
| EPS (Diluted) | -0.98 | -1.32 | -2.09 | -2.38 | -1.34 | -2.63 | Upgrade
|
| Free Cash Flow | -158.99 | -200.99 | -239.25 | -225.71 | -206.26 | -181.05 | Upgrade
|
| Free Cash Flow Per Share | -0.73 | -1.03 | -1.52 | -1.58 | -1.52 | -1.50 | Upgrade
|
| Gross Margin | - | - | - | - | -92.99% | - | Upgrade
|
| Operating Margin | - | -1170372.73% | -331044.21% | -215087.18% | -157.94% | - | Upgrade
|
| Profit Margin | - | -1170863.64% | -344489.47% | -218214.10% | -159.57% | - | Upgrade
|
| Free Cash Flow Margin | - | -913609.09% | -251841.05% | -144685.90% | -180.79% | - | Upgrade
|
| EBITDA | -212.48 | -243.84 | -300.29 | -321.24 | -169.74 | -250.81 | Upgrade
|
| EBITDA Margin | - | - | - | - | -148.78% | - | Upgrade
|
| D&A For EBITDA | 12.54 | 13.64 | 14.2 | 14.3 | 10.45 | 7.44 | Upgrade
|
| EBIT | -225.02 | -257.48 | -314.49 | -335.54 | -180.19 | -258.24 | Upgrade
|
| EBIT Margin | - | - | - | - | -157.94% | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.